228 related articles for article (PubMed ID: 30498095)
1. Clinical Development of Novel Drug-Radiotherapy Combinations.
Ahmad SS; Crittenden MR; Tran PT; Kluetz PG; Blumenthal GM; Bulbeck H; Baird RD; Williams KJ; Illidge T; Hahn SM; Lawrence TS; Spears PA; Walker AJ; Sharma RA
Clin Cancer Res; 2019 Mar; 25(5):1455-1461. PubMed ID: 30498095
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of new drug-radiotherapy combinations.
Sharma RA; Plummer R; Stock JK; Greenhalgh TA; Ataman O; Kelly S; Clay R; Adams RA; Baird RD; Billingham L; Brown SR; Buckland S; Bulbeck H; Chalmers AJ; Clack G; Cranston AN; Damstrup L; Ferraldeschi R; Forster MD; Golec J; Hagan RM; Hall E; Hanauske AR; Harrington KJ; Haswell T; Hawkins MA; Illidge T; Jones H; Kennedy AS; McDonald F; Melcher T; O'Connor JP; Pollard JR; Saunders MP; Sebag-Montefiore D; Smitt M; Staffurth J; Stratford IJ; Wedge SR;
Nat Rev Clin Oncol; 2016 Oct; 13(10):627-42. PubMed ID: 27245279
[TBL] [Abstract][Full Text] [Related]
3. Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.
Marciscano AE; Walker JM; McGee HM; Kim MM; Kunos CA; Monjazeb AM; Shiao SL; Tran PT; Ahmed MM
J Immunother Cancer; 2018 Jan; 6(1):6. PubMed ID: 29375032
[TBL] [Abstract][Full Text] [Related]
4. Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico.
Falls KC; Sharma RA; Lawrence YR; Amos RA; Advani SJ; Ahmed MM; Vikram B; Coleman CN; Prasanna PG
Radiat Res; 2018 Oct; 190(4):350-360. PubMed ID: 30280985
[TBL] [Abstract][Full Text] [Related]
5. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.
Milas L; Mason KA; Crane CH; Liao Z; Masferrer J
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):15-24. PubMed ID: 12800601
[TBL] [Abstract][Full Text] [Related]
6. Personalized radiotherapy: concepts, biomarkers and trial design.
Ree AH; Redalen KR
Br J Radiol; 2015 Jul; 88(1051):20150009. PubMed ID: 25989697
[TBL] [Abstract][Full Text] [Related]
7. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
8. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017.
Okunieff P; Casey-Sawicki K; Lockney NA; Hoppe BS; Enderling H; Pinnix C; Welsh J; Krishnan S; Yothers G; Brown M; Knox S; Bristow R; Spellman P; Mitin T; Nabavizadeh N; Jaboin J; Manning HC; Feng F; Galbraith S; Solanki AA; Harkenrider MM; Tuli R; Decker RH; Finkelstein SE; Hsu CC; Ha CS; Jagsi R; Shumway D; Daly M; Wang TJC; Fitzgerald TJ; Laurie F; Marshall DT; Raben D; Constine L; Thomas CR; Kachnic LA
Clin Cancer Res; 2018 Aug; 24(15):3500-3509. PubMed ID: 29661779
[TBL] [Abstract][Full Text] [Related]
9. Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy.
Arcangeli S; Jereczek-Fossa BA; Alongi F; Aristei C; Becherini C; Belgioia L; Buglione M; Caravatta L; D'Angelillo RM; Filippi AR; Fiore M; Genovesi D; Greco C; Livi L; Magrini SM; Marvaso G; Mazzola R; Meattini I; Merlotti A; Palumbo I; Pergolizzi S; Ramella S; Ricardi U; Russi E; Trovò M; Sindoni A; Valentini V; Corvò R
Crit Rev Oncol Hematol; 2019 Feb; 134():87-103. PubMed ID: 30658886
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
Reboul FL
Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
[TBL] [Abstract][Full Text] [Related]
11. Model Selection for the Preclinical Development of New Drug-Radiotherapy Combinations.
Singh J; Hatcher S; Ku AA; Ding Z; Feng FY; Sharma RA; Pfister SX
Clin Oncol (R Coll Radiol); 2021 Nov; 33(11):694-704. PubMed ID: 34474951
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
[TBL] [Abstract][Full Text] [Related]
13. Implementation of three dimensional conformal radiation therapy: prospects, opportunities, and challenges.
Vijayakumar S; Chen GT
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):979-83. PubMed ID: 7493859
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
15. State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.
Käsmann L; Eze C; Dantes M; Roengvoraphoj O; Niyazi M; Belka C; Manapov F
Eur J Cancer; 2019 Feb; 108():50-54. PubMed ID: 30648629
[TBL] [Abstract][Full Text] [Related]
16. When can a drug be considered synergic with radiotherapy?
Gambacorta MA; Macchia G; Deodato F; Murino P; Barba MC; Manfrida S
Rays; 2004; 29(3):291-9. PubMed ID: 15603301
[TBL] [Abstract][Full Text] [Related]
17. The clinical development of molecularly targeted agents in combination with radiation therapy: a pharmaceutical perspective.
Ataman OU; Sambrook SJ; Wilks C; Lloyd A; Taylor AE; Wedge SR
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e447-54. PubMed ID: 22819210
[TBL] [Abstract][Full Text] [Related]
18. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
19. Evolution of the Radiation Therapy Oncology Group clinical trials for head and neck cancer.
Fu KK; Cooper JS; Marcial VA; Laramore GE; Pajak TF; Jacobs J; Al-Sarraf M; Forastiere AA; Cox JD
Int J Radiat Oncol Biol Phys; 1996 Jun; 35(3):425-38. PubMed ID: 8655364
[TBL] [Abstract][Full Text] [Related]
20. Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.
Khan MK; Nasti TH; Buchwald ZS; Weichselbaum RR; Kron SJ
Cancer J; 2019; 25(2):106-115. PubMed ID: 30896532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
